13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q2 2023 · Filed May 11, 2023 · Accession 0000950123-23-004367
Total Value
$48.0M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics AG | CRSP | 498,558 | $22.5M | 47.01% |
| 2 | Gritstone Oncology, Inc. | 39868T105 | 3,561,150 | $9.9M | 20.64% |
| 3 | Passage Bio, Inc. | PASG | 4,959,769 | $4.7M | 9.90% |
| 4 | CymaBay Therapeutics, Inc. | 23257D103 | 543,753 | $4.7M | 9.88% |
| 5 | Adverum Biotechnologies, Inc. | 00773U108 | 5,068,233 | $3.6M | 7.58% |
| 6 | Aligos Therapeutics, Inc. | ALGS | 2,320,381 | $2.0M | 4.23% |
| 7 | Minerva Surgical Inc. | 60343F106 | 1,673,700 | $367,377 | 0.77% |